Literature DB >> 30628844

Low expression of CD80 predicts for poor prognosis in patients with gastric adenocarcinoma.

Xing-Yu Feng1,2,3, Lin Lu4,5, Ke-Feng Wang1,3, Bao-Yan Zhu1,3, Xi-Zhi Wen1,3, Rui-Qing Peng1,3, Ya Ding1,3, Dan-Dan Li1,3, Jing-Jing Li1,3, Yong Li2, Xiao-Shi Zhang1,3.   

Abstract

AIM: To study the expression and prognostic significance of CD80 in patients with gastric adenocarcinoma. Materials & methods: Real-time quantitative PCR, western blot and immunohistochemistry were performed to detect the expression of CD80 in gastric cancer tissues and matched adjacent normal tissues. Double immunohistochemical staining was performed to preliminary examine the relationship between CD80+ cells and CD8+ cytotoxic T lymphocytes.
RESULTS: The expression of CD80 was downregulated in tumor tissues compared with normal tissues (p = 0.002). Immunohistochemistry analysis showed that 49 (39.8%) of 123 patients with gastric cancer demonstrated reduced CD80 expression, which was correlated with the tumor differentiation grade.
CONCLUSION: Our data suggest that reduced CD80 expression independently predicts a poor prognosis in patients with gastric adenocarcinoma.

Entities:  

Keywords:  CD80; cytotoxic T lymphocytes; gastric cancer; prognosis

Mesh:

Substances:

Year:  2019        PMID: 30628844     DOI: 10.2217/fon-2018-0420

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  7 in total

1.  Inhibition of ITGB1-DT expression delays the growth and migration of stomach adenocarcinoma and improves the prognosis of cancer patients using the bioinformatics and cell model analysis.

Authors:  Ni Jiang; Qiang Guo; Qing Luo
Journal:  J Gastrointest Oncol       Date:  2022-04

2.  Development of Cancer Immunotherapies.

Authors:  Diana C DeLucia; John K Lee
Journal:  Cancer Treat Res       Date:  2022

Review 3.  Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways.

Authors:  Barbara Seliger; Chiara Massa
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

4.  CCR9 Promotes Migration and Invasion of Lung Adenocarcinoma Cancer Stem Cells.

Authors:  Lin Lu; Huan Du; Haowei Huang; Chenxi Wang; Peipei Wang; Zhiqiang Zha; Yong Wu; Xia Liu; Chengyin Weng; Xisheng Fang; Baoxiu Li; Haibo Mao; Lina Wang; Mingmei Guan; Guolong Liu
Journal:  Int J Med Sci       Date:  2020-03-26       Impact factor: 3.738

5.  Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor.

Authors:  Takashi Sato; Kiyoshi Takagi; Mitsunori Higuchi; Hiroko Abe; Michie Kojimahara; Miho Sagawa; Megumi Tanaki; Yasuhiro Miki; Takashi Suzuki; Hiroshi Hojo
Journal:  Acta Histochem Cytochem       Date:  2022-02-11       Impact factor: 1.938

6.  The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.

Authors:  Mark F Maurer; Katherine E Lewis; Joseph L Kuijper; Dan Ardourel; Chelsea J Gudgeon; Siddarth Chandrasekaran; Sherri L Mudri; Kayla N Kleist; Chris Navas; Martin F Wolfson; Mark W Rixon; Ryan Swanson; Stacey R Dillon; Steven D Levin; Yengo Raymond Kimbung; Masato Akutsu; Derek T Logan; Björn Walse; Kristine M Swiderek; Stanford L Peng
Journal:  Nat Commun       Date:  2022-04-04       Impact factor: 17.694

7.  A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.

Authors:  Qin Yang; Han Gong; Jing Liu; Mao Ye; Wen Zou; Hui Li
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.